Rob Rodrigues

Partner

Bio

Rob Rodrigues is a seasoned litigator specializing in high-stakes business and intellectual property disputes in Brazil. Renowned for his strategic acumen, Rob delivers unmatched expertise to FORTUNE 500 companies and dynamic startups alike. He expertly navigates complex legal landscapes, ensuring robust patent portfolio management for top-tier life sciences and telecommunications firms. His deep market insight positions him as a first-choice advisor for both acquisition and enforcement actions.

Rob's excellence has been recognized by a number of leading publications. In 2024, Lexology listed him as a Legal Influencer in Dispute Resolution. Chambers describes Rob as a "superb litigator", "a very competent professional", and "outstanding in providing business-oriented advice." Who's Who Legal praises "his top-tier practice advising clients on life sciences-related patent litigation." The Legal 500 reports that clients describe Rob as someone "who stands out for his strong background in both the IP area, both in terms of litigation and in relation to more technical topics." Client testimonials in IAM Strategy 300 laud him for his "deep understanding of IP issues and keen strategic insight, which he leverages to add value and monetise portfolios."

Throughout his career, Rob has spearheaded multiple preliminary injunction proceedings and trials for global companies in Brazil. He also facilitates monumental IP asset transactions, with a keen eye on managing risks.

A Stanford Law School LL.M. alumnus, Rob served as a lead editor of the Stanford Technology Law Review. He has contributed extensively to global technology law journals and currently holds an editorial role at the Kluwer IP Blog.

Education

LL.M. in Law, Science and Technology, from Stanford Law School.

Residential Scholarship at Hoover IP2 Summer Teaching Institute.

J.D. from Universidade Federal do Rio de Janeiro (UFRJ).

Languages

Portuguese, English, Spanish

Publications

Life Sciences & Healthcare Patents
Life Sciences & Healthcare Patents

ANVISA new rules allowing changes on marketing approval “waiting list”

ANVISA’s new 2025–2026 Operational Tactical Plan aims to reduce marketing approval backlogs by allowing applicants to replace pending submissions before formal review and by granting priority review for GLP‑1 receptor agonists.
2025
5
min read
Pharmaceutical & Biotechnology Patents
Pharmaceutical & Biotechnology Patents

Microbial consortium: How to obtain patent protection in Brazil

The scientific significance of microbial consortia, their applications in biotechnology, and the challenges of obtaining patent protection in Brazil under BRPTO regulations.
2025
7
min read
News
News

Brazil Welcomes New Intellectual Property Powerhouse: RNA Law

A new chapter in Brazil’s IP scene has begun with the launch of RNA Law, an elite boutique firm dedicated to IP litigation, prosecution, and transactions.
2024
3
min read
Rob Rodrigues
Tatiana Alves
Karlo Tinoco
Brenno Telles, Ciro Albuquerque
Patent Filing & Examination
Patent Filing & Examination

BRPTO publishes new workflow for patent examination in appeal stage

BRPTO introduces a new appeal stage workflow to improve patent examination, focusing on enhancing consistency and efficiency in Brazil’s patent appeal process
2024
5
min read